Welcome to Medications.com

Cardizem LA Information

What's inside Cardizem LA

Cardizem LA Active Ingredients: diltiazem hydrochloride, details.
Cardizem LA Dosages & Strengths
Strength Format Route Strength Class
Cardizem LA 240 mg/24 hours tablet, extended release oral 1.0 each OTC
Cardizem LA 300 mg/24 hours tablet, extended release oral 1.0 each OTC
Cardizem LA 360 mg/24 hours tablet, extended release oral 1.0 each OTC
Cardizem LA 420 mg/24 hours tablet, extended release oral 1.0 each OTC
Cardizem LA 180 mg/24 hours tablet, extended release oral 1.0 each OTC
Cardizem LA 120 mg/24 hours tablet, extended release oral 1.0 each OTC

Recent Cardizem LA Side Effects

Posted by shiralee72 about 1 year ago
Taking it for several years. Most recent blood test showed very high potassium levels, causing doctor to have great concern....


Cardizem LA in the News

Melnyk urges change at Biovail, warns action - Business Edge
More recently, Biovail said that a US federal grand jury is investigating activities surrounding the 2003 launch of Cardizem LA, a major initiative while ...
Fri Mar 07 02:56:19 -0500 2008

Stocks extend gains on M&A activity despite unsettling US ... - AOL Canada
... to $13.25 after the company said it is the target of US federal grand jury investigation into the 2003 commercial launch of its Cardizem heart drug. ...
Wed Feb 27 23:05:18 -0500 2008

Registered Nurse - RN - ADVANCE
Monitors special drugs (ie, Dopamine, Lidocaine, Dobutrex, and Cardizem) and other cardiac drugs, as per protocol. E7. Assesses patients in an on going ...
Fri Feb 29 14:03:18 -0500 2008


Cardizem LA Chemical Information

diltiazem hydrochloride - A benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility. Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. (NCI04)





© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea